首页 > 最新文献

Inflammatory Bowel Diseases最新文献

英文 中文
Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis: A Multicenter Cohort Study. 小儿溃疡性直肠炎的长期病程和预后因素:多中心队列研究
IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-19 DOI: 10.1093/ibd/izae266
Ayako Miyazawa, Ryusuke Nambu, Hirotaka Shimizu, Takahiro Kudo, Takuya Nishizawa, Hideki Kumagai, Shin-Ichiro Hagiwara, Emiri Kaji, Tatsuki Mizuochi, Shingo Kurasawa, Fumihiko Kakuta, Takashi Ishige, Toshiaki Shimizu, Itaru Iwama, Katsuhiro Arai

Background: Although ulcerative proctitis (UP) in children is considered relatively mild, some patients have proximal disease extension and require immunosuppressive treatment. We investigated clinical characteristics and course of refractory UP in a multicenter pediatric cohort.

Methods: Analyzing data obtained between 2013 and 2022 at 10 institutions specializing in pediatric inflammatory bowel disease, we elucidated natural history and factors predicting a need for immunosuppressive UP treatment. We compared patients given immunosuppressants and/or biologic agents (immunosuppressive treatment group) with those given 5-aminosalicylic acid (5-ASA) alone (5-ASA group).

Results: Fifty-five patients were followed for 3.5 years. The median Pediatric Ulcerative Colitis Activity Index at diagnosis was 20. The commonest treatment, 5-ASA suppository monotherapy in 40% of patients, showed the worst compliance. Clinical remission was achieved at least once in 95% of all patients. Disease extension beyond the splenic flexure occurred in 51%. Immunosuppressive treatment was given to 37%; biologic agents were used for 18%. Rates of endoscopically demonstrated inflammation, including Ra/Rs at diagnosis and extension beyond the left-sided colon, were higher in the immunosuppressive treatment group (70% vs 38%, P < 0.05; 95% vs 27%, P < 0.0001). The log-rank test and multivariate Cox proportional hazards regression showed that time to first clinical remission exceeding 3 months predicted the need for biologics.

Conclusion: The typical initial treatment of pediatric UP was 5-ASA suppositories, despite poor compliance. Biologics or other immunosuppressive treatments were needed in 37% of patients. Close follow-up with adjustment of treatment should be considered in children with UP as its clinical course varies.

背景:虽然儿童溃疡性直肠炎(UP)被认为是相对较轻的疾病,但有些患者的疾病会向近端扩展,需要接受免疫抑制治疗。我们在一个多中心儿科队列中调查了难治性溃疡性直肠炎的临床特征和病程:我们分析了2013年至2022年期间在10家儿科炎症性肠病专科机构获得的数据,阐明了自然病史和预测需要接受免疫抑制性UP治疗的因素。我们将接受免疫抑制剂和/或生物制剂治疗的患者(免疫抑制剂治疗组)与仅接受5-氨基水杨酸(5-ASA)治疗的患者(5-ASA治疗组)进行了比较:对 55 名患者进行了为期 3.5 年的随访。结果:对 55 名患者进行了为期 3.5 年的随访,诊断时的小儿溃疡性结肠炎活动指数中位数为 20。最常见的治疗方法是 5-ASA 栓剂单药治疗,有 40% 的患者接受了这种治疗,但依从性最差。95%的患者至少有一次临床缓解。51%的患者病情扩展至脾曲以外。37%的患者接受了免疫抑制治疗;18%的患者使用了生物制剂。免疫抑制治疗组的内镜下炎症(包括诊断时的Ra/Rs)发生率更高(70% vs 38%,P 结论:免疫抑制治疗组的内镜下炎症发生率更高(70% vs 38%,P 结论:免疫抑制治疗组的内镜下炎症发生率更高,包括诊断时的Ra/Rs):尽管依从性较差,但小儿 UP 的典型初始治疗方法是 5-ASA 栓剂。37%的患者需要使用生物制剂或其他免疫抑制剂。由于UP的临床过程各不相同,因此应考虑对儿童UP患者进行密切随访并调整治疗方法。
{"title":"Long-Term Course and Prognostic Factors in Pediatric Ulcerative Proctitis: A Multicenter Cohort Study.","authors":"Ayako Miyazawa, Ryusuke Nambu, Hirotaka Shimizu, Takahiro Kudo, Takuya Nishizawa, Hideki Kumagai, Shin-Ichiro Hagiwara, Emiri Kaji, Tatsuki Mizuochi, Shingo Kurasawa, Fumihiko Kakuta, Takashi Ishige, Toshiaki Shimizu, Itaru Iwama, Katsuhiro Arai","doi":"10.1093/ibd/izae266","DOIUrl":"https://doi.org/10.1093/ibd/izae266","url":null,"abstract":"<p><strong>Background: </strong>Although ulcerative proctitis (UP) in children is considered relatively mild, some patients have proximal disease extension and require immunosuppressive treatment. We investigated clinical characteristics and course of refractory UP in a multicenter pediatric cohort.</p><p><strong>Methods: </strong>Analyzing data obtained between 2013 and 2022 at 10 institutions specializing in pediatric inflammatory bowel disease, we elucidated natural history and factors predicting a need for immunosuppressive UP treatment. We compared patients given immunosuppressants and/or biologic agents (immunosuppressive treatment group) with those given 5-aminosalicylic acid (5-ASA) alone (5-ASA group).</p><p><strong>Results: </strong>Fifty-five patients were followed for 3.5 years. The median Pediatric Ulcerative Colitis Activity Index at diagnosis was 20. The commonest treatment, 5-ASA suppository monotherapy in 40% of patients, showed the worst compliance. Clinical remission was achieved at least once in 95% of all patients. Disease extension beyond the splenic flexure occurred in 51%. Immunosuppressive treatment was given to 37%; biologic agents were used for 18%. Rates of endoscopically demonstrated inflammation, including Ra/Rs at diagnosis and extension beyond the left-sided colon, were higher in the immunosuppressive treatment group (70% vs 38%, P < 0.05; 95% vs 27%, P < 0.0001). The log-rank test and multivariate Cox proportional hazards regression showed that time to first clinical remission exceeding 3 months predicted the need for biologics.</p><p><strong>Conclusion: </strong>The typical initial treatment of pediatric UP was 5-ASA suppositories, despite poor compliance. Biologics or other immunosuppressive treatments were needed in 37% of patients. Close follow-up with adjustment of treatment should be considered in children with UP as its clinical course varies.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing Gut Microbiome Research for Inflammatory Bowel Diseases Therapy: Addressing Study Limitations and Advancing Clinical Translation. 加强肠道微生物组研究,促进炎症性肠病治疗:解决研究局限性,推进临床转化。
IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-18 DOI: 10.1093/ibd/izae275
Kaili Lin, Taifu You, Sheng Li
{"title":"Enhancing Gut Microbiome Research for Inflammatory Bowel Diseases Therapy: Addressing Study Limitations and Advancing Clinical Translation.","authors":"Kaili Lin, Taifu You, Sheng Li","doi":"10.1093/ibd/izae275","DOIUrl":"10.1093/ibd/izae275","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Associated With Biologic Therapy After Ileal Pouch-Anal Anastomosis in Patients With Ulcerative Colitis. 溃疡性结肠炎患者回肠袋-肛门吻合术后生物疗法的相关因素
IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-14 DOI: 10.1093/ibd/izae272
Maya Fischman, Lihi Godny, Adi Friedenberg, Revital Barkan, Ian White, Nir Wasserberg, Keren Rabinowitz, Irit Avni-Biron, Hagar Banai, Yifat Snir, Yelena Broitman, Henit Yanai, Iris Dotan, Jacob E Ollech

Background: Patients with ulcerative colitis (UC) undergoing proctocolectomy and ileal pouch-anal anastomosis (IPAA) may eventually require biologic therapy. Factors associated with biologic therapy after IPAA have not been previously studied.

Methods: All patients with UC after total proctocolectomy and IPAA who were followed at Rabin Medical Center comprehensive pouch clinic and who consented to prospective observational follow-up were included. The primary outcome was the initiation of biologic therapy after IPAA. Cox proportional hazard models were used to evaluate potential associations.

Results: Out of 400 patients receiving their care at the pouch clinic, 148 patients consented to prospective observational follow-up and constituted the study cohort. The median age at diagnosis was 21 years and the age at IPAA was 30 years. Median time-to-biologic therapy initiation post-IPAA was 9.2 years, with 34 patients (23%) initiating biologic therapy: Associated factors for initiating biologic therapy post-IPAA were preoperative treatment with biologic therapy and immunomodulatory therapy (hazard ratio [HR] 6.1 and 3.6, respectively, P < .001); Arab descent (HR 5.3, P < .001); heterozygosity of NOD2 variant rs2066845 (HR 5.1, P = .03); past smoking status (HR 2.3, P = .03); 3-stage IPAA (HR 2.3, P = .02); immediate postoperative complications (HR 2.1, P = .033); and pediatric-onset UC (HR 2.1, P = .03). None of the patients undergoing IPAA due to dysplasia (n = 27) required biologic therapy.

Conclusions: Several demographic, disease-related, surgery-related, and genetic factors associated with post-IPAA biologic therapy were identified. Physicians treating patients with UC undergoing colectomy should incorporate these factors into their decision-making process. These patients may benefit from closer postoperative follow-up, and earlier initiation of biologic therapy should be considered.

背景:接受直肠切除术和回肠袋-肛门吻合术(IPAA)的溃疡性结肠炎(UC)患者最终可能需要接受生物治疗。此前尚未研究过 IPAA 术后生物治疗的相关因素:方法:纳入所有在拉宾医疗中心综合肠袋门诊接受随访并同意接受前瞻性观察随访的全直肠切除术和IPAA术后UC患者。主要结果是在IPAA术后开始接受生物治疗。采用Cox比例危险模型评估潜在的关联性:在400名接受Pouch诊所治疗的患者中,有148名患者同意进行前瞻性观察随访,并构成了研究队列。诊断时的中位年龄为21岁,IPAA时的中位年龄为30岁。IPAA后开始接受生物治疗的中位时间为9.2年,其中34名患者(23%)开始接受生物治疗:IPAA后开始生物治疗的相关因素是术前接受生物治疗和免疫调节治疗(危险比[HR]分别为6.1和3.6,P 结论:IPAA后开始生物治疗的相关因素是术前接受生物治疗和免疫调节治疗(危险比[HR]分别为6.1和3.6,P 结论):研究发现了一些与IPAA术后生物治疗相关的人口统计学因素、疾病相关因素、手术相关因素和遗传因素。治疗接受结肠切除术的 UC 患者的医生应在决策过程中考虑这些因素。这些患者可能会受益于更密切的术后随访,并应考虑尽早开始生物治疗。
{"title":"Factors Associated With Biologic Therapy After Ileal Pouch-Anal Anastomosis in Patients With Ulcerative Colitis.","authors":"Maya Fischman, Lihi Godny, Adi Friedenberg, Revital Barkan, Ian White, Nir Wasserberg, Keren Rabinowitz, Irit Avni-Biron, Hagar Banai, Yifat Snir, Yelena Broitman, Henit Yanai, Iris Dotan, Jacob E Ollech","doi":"10.1093/ibd/izae272","DOIUrl":"https://doi.org/10.1093/ibd/izae272","url":null,"abstract":"<p><strong>Background: </strong>Patients with ulcerative colitis (UC) undergoing proctocolectomy and ileal pouch-anal anastomosis (IPAA) may eventually require biologic therapy. Factors associated with biologic therapy after IPAA have not been previously studied.</p><p><strong>Methods: </strong>All patients with UC after total proctocolectomy and IPAA who were followed at Rabin Medical Center comprehensive pouch clinic and who consented to prospective observational follow-up were included. The primary outcome was the initiation of biologic therapy after IPAA. Cox proportional hazard models were used to evaluate potential associations.</p><p><strong>Results: </strong>Out of 400 patients receiving their care at the pouch clinic, 148 patients consented to prospective observational follow-up and constituted the study cohort. The median age at diagnosis was 21 years and the age at IPAA was 30 years. Median time-to-biologic therapy initiation post-IPAA was 9.2 years, with 34 patients (23%) initiating biologic therapy: Associated factors for initiating biologic therapy post-IPAA were preoperative treatment with biologic therapy and immunomodulatory therapy (hazard ratio [HR] 6.1 and 3.6, respectively, P < .001); Arab descent (HR 5.3, P < .001); heterozygosity of NOD2 variant rs2066845 (HR 5.1, P = .03); past smoking status (HR 2.3, P = .03); 3-stage IPAA (HR 2.3, P = .02); immediate postoperative complications (HR 2.1, P = .033); and pediatric-onset UC (HR 2.1, P = .03). None of the patients undergoing IPAA due to dysplasia (n = 27) required biologic therapy.</p><p><strong>Conclusions: </strong>Several demographic, disease-related, surgery-related, and genetic factors associated with post-IPAA biologic therapy were identified. Physicians treating patients with UC undergoing colectomy should incorporate these factors into their decision-making process. These patients may benefit from closer postoperative follow-up, and earlier initiation of biologic therapy should be considered.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on: "The Burden of Psychiatric Manifestations in Inflammatory Bowel Diseases: A Systematic Review With Meta-analysis". 评论"炎症性肠病的精神症状负担:带 Meta 分析的系统性综述》。
IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-14 DOI: 10.1093/ibd/izae260
Ganesh Bushi, Muhammed Shabil, Sanjit Sah
{"title":"Comment on: \"The Burden of Psychiatric Manifestations in Inflammatory Bowel Diseases: A Systematic Review With Meta-analysis\".","authors":"Ganesh Bushi, Muhammed Shabil, Sanjit Sah","doi":"10.1093/ibd/izae260","DOIUrl":"https://doi.org/10.1093/ibd/izae260","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Why Symptoms Linger in Quiescent Crohn's Disease: Investigating the Impact of Sulfidogenic Microbes and Sulfur Metabolic Pathways. 克罗恩病静止期症状为何挥之不去?研究产硫微生物和硫代谢途径的影响。
IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-14 DOI: 10.1093/ibd/izae238
Jonathan Golob, Krishna Rao, Jeffrey A Berinstein, Prashant Singh, William D Chey, Chung Owyang, Nobuhiko Kamada, Peter D R Higgins, Vincent Young, Shrinivas Bishu, Allen A Lee

Introduction: Even in the absence of inflammation, persistent symptoms in patients with Crohn's disease (CD) are prevalent and worsen quality of life. We previously demonstrated enrichment in sulfidogenic microbes in quiescent Crohn's disease patients with (qCD + S) vs without persistent GI symptoms (qCD-S). Thus, we hypothesized that sulfur metabolic pathways would be enriched in stool while differentially abundant microbes would be associated with important sulfur metabolic pathways in qCD + S.

Methods: We performed a multicenter observational study nested within SPARC IBD. Quiescent inflammation was defined by fecal calprotectin level < 150 mcg/g. Persistent symptoms were defined by CD-PRO2. Active CD (aCD) and non-IBD diarrhea-predominant irritable bowel syndrome (IBS-D) were included as controls.

Results: Thirty-nine patients with qCD + S, 274 qCD-S, 21 aCD, and 40 IBS-D underwent paired shotgun metagenomic sequencing and untargeted metabolomic profiling. The fecal metabolome in qCD + S was significantly different relative to qCD-S and IBS-D but not aCD. Patients with qCD + S were enriched in sulfur-containing amino acid pathways, including cysteine and methionine, as well as serine, glycine, and threonine. Glutathione and nicotinate/nicotinamide pathways were also enriched in qCD + S relative to qCD-S, suggestive of mitochondrial dysfunction, a downstream target of H2S signaling. Multi-omic integration demonstrated that enriched microbes in qCD + S were associated with important sulfur metabolic pathways. Bacterial sulfur metabolic genes, including CTH, isfD, sarD, and asrC, were dysregulated in qCD + S. Finally, sulfur metabolites with and without sulfidogenic microbes showed good accuracy in predicting the presence of qCD + S.

Discussion: Microbial-derived sulfur pathways and downstream mitochondrial function are perturbed in qCD + S, which implicate H2S signaling in the pathogenesis of this condition. Future studies will determine whether targeting H2S pathways results in improved quality of life in qCD + S.

导言:即使没有炎症,克罗恩病(CD)患者的持续症状也很普遍,并使生活质量下降。我们以前曾证实,在有持续性消化道症状(qCD + S)和无持续性消化道症状(qCD-S)的静止期克罗恩病患者中,硫化物生成微生物富集。因此,我们假设硫代谢途径将在粪便中富集,而在 qCD + S 中,不同数量的微生物将与重要的硫代谢途径有关:我们在 SPARC IBD 中进行了一项多中心观察性研究。方法:我们在 SPARC IBD 中进行了多中心观察性研究:39 名 qCD + S 患者、274 名 qCD-S 患者、21 名 aCD 患者和 40 名 IBS-D 患者接受了成对猎枪元基因组测序和非靶向代谢组分析。qCD + S患者的粪便代谢组与qCD-S和IBS-D患者有显著差异,但与aCD患者无显著差异。qCD + S患者富含含硫氨基酸途径,包括半胱氨酸和蛋氨酸,以及丝氨酸、甘氨酸和苏氨酸。相对于 qCD-S,谷胱甘肽和烟酸/烟酰胺途径也在 qCD + S 中富集,这表明线粒体功能障碍是 H2S 信号转导的下游目标。多组学整合表明,qCD + S 中富集的微生物与重要的硫代谢途径有关。包括 CTH、isfD、sarD 和 asrC 在内的细菌硫代谢基因在 qCD + S 中调控失调。最后,含硫微生物和不含硫微生物的硫代谢物在预测 qCD + S 的存在方面表现出良好的准确性:讨论:在 qCD + S 中,微生物衍生的硫通路和下游线粒体功能受到干扰,这表明 H2S 信号与这种病症的发病机制有关。未来的研究将确定靶向 H2S 通路是否能改善 qCD + S 患者的生活质量。
{"title":"Why Symptoms Linger in Quiescent Crohn's Disease: Investigating the Impact of Sulfidogenic Microbes and Sulfur Metabolic Pathways.","authors":"Jonathan Golob, Krishna Rao, Jeffrey A Berinstein, Prashant Singh, William D Chey, Chung Owyang, Nobuhiko Kamada, Peter D R Higgins, Vincent Young, Shrinivas Bishu, Allen A Lee","doi":"10.1093/ibd/izae238","DOIUrl":"10.1093/ibd/izae238","url":null,"abstract":"<p><strong>Introduction: </strong>Even in the absence of inflammation, persistent symptoms in patients with Crohn's disease (CD) are prevalent and worsen quality of life. We previously demonstrated enrichment in sulfidogenic microbes in quiescent Crohn's disease patients with (qCD + S) vs without persistent GI symptoms (qCD-S). Thus, we hypothesized that sulfur metabolic pathways would be enriched in stool while differentially abundant microbes would be associated with important sulfur metabolic pathways in qCD + S.</p><p><strong>Methods: </strong>We performed a multicenter observational study nested within SPARC IBD. Quiescent inflammation was defined by fecal calprotectin level < 150 mcg/g. Persistent symptoms were defined by CD-PRO2. Active CD (aCD) and non-IBD diarrhea-predominant irritable bowel syndrome (IBS-D) were included as controls.</p><p><strong>Results: </strong>Thirty-nine patients with qCD + S, 274 qCD-S, 21 aCD, and 40 IBS-D underwent paired shotgun metagenomic sequencing and untargeted metabolomic profiling. The fecal metabolome in qCD + S was significantly different relative to qCD-S and IBS-D but not aCD. Patients with qCD + S were enriched in sulfur-containing amino acid pathways, including cysteine and methionine, as well as serine, glycine, and threonine. Glutathione and nicotinate/nicotinamide pathways were also enriched in qCD + S relative to qCD-S, suggestive of mitochondrial dysfunction, a downstream target of H2S signaling. Multi-omic integration demonstrated that enriched microbes in qCD + S were associated with important sulfur metabolic pathways. Bacterial sulfur metabolic genes, including CTH, isfD, sarD, and asrC, were dysregulated in qCD + S. Finally, sulfur metabolites with and without sulfidogenic microbes showed good accuracy in predicting the presence of qCD + S.</p><p><strong>Discussion: </strong>Microbial-derived sulfur pathways and downstream mitochondrial function are perturbed in qCD + S, which implicate H2S signaling in the pathogenesis of this condition. Future studies will determine whether targeting H2S pathways results in improved quality of life in qCD + S.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Risk of Venous Thromboembolism in Children With Inflammatory Bowel Disease. 炎症性肠病患儿的静脉血栓栓塞风险。
IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-14 DOI: 10.1093/ibd/izae249
Philip R Harvey, David McNulty, Benjamin Coupland, Polychronis Kemos, Nicholas M Croft, Nigel J Trudgill

Background: Recent studies of children with inflammatory bowel disease (IBD) demonstrate an increased venous thromboembolism (VTE) risk. However, estimates of risk are variable and case numbers are limited. The aim of this study was to provide national estimates of the risk of VTE in children with IBD.

Methods: Hospital Episode Statistics was used to identify patients diagnosed with either IBD or VTE before reaching 18 years of age between 2001 and 2019. Populations and subgroups are described, and the risks of developing VTE in the general and IBD populations were calculated.

Results: Children with VTE following a diagnosis of IBD or in the previous 6 months (n = 85) and with VTE without IBD (n = 4160) were studied. The absolute risk in children with IBD was 9.42 (95% confidence interval [CI], 7.4-11.4) per 10 000 patient-years, compared with 0.18 (95% CI, 18-0.19) in children without IBD. Between 6 months prior to and 1 year following IBD diagnosis was the highest absolute risk period for VTE (18.0; 95% CI, 13.7-22.4). The relative risk of VTE in children with IBD vs children without IBD was greatest in younger patient groups: the relative risk for the age band 0 to 8 years was 96.5 (95% CI, 51.8-179.9) and for 9 to 11 years was 153.1 (95% CI, 81.2-288.8) vs 14.3 (95% CI, 10.3-20.0) for 15 to 17 years. Cerebral venous sinus thrombosis represented 17.6% of pediatric VTE events in IBD patients compared with 4.2% in children without IBD (P = .001).

Conclusions: This study confirms the increased risk of VTE in children with IBD compared with children without IBD. The time of greatest VTE risk was around diagnosis. Cerebral venous sinus thrombosis was significantly more common in children with IBD than other children.

背景:最近对患有炎症性肠病(IBD)的儿童进行的研究表明,静脉血栓栓塞症(VTE)的风险增加。然而,对风险的估算不尽相同,病例数量也很有限。本研究的目的是提供全国性的 IBD 儿童 VTE 风险估计值。方法:使用医院病例统计来识别 2001 年至 2019 年期间年满 18 岁之前被诊断为 IBD 或 VTE 的患者。对人群和亚组进行了描述,并计算了普通人群和IBD人群发生VTE的风险:研究对象包括确诊 IBD 后或之前 6 个月内发生 VTE 的儿童(n = 85)和未患 IBD 而发生 VTE 的儿童(n = 4160)。IBD 患儿的绝对风险为每 10,000 患者年 9.42 例(95% 置信区间 [CI],7.4-11.4),而无 IBD 患儿的绝对风险为每 10,000 患者年 0.18 例(95% 置信区间 [CI],18-0.19)。IBD 诊断前 6 个月至诊断后 1 年是 VTE 绝对风险最高的时期(18.0;95% CI,13.7-22.4)。IBD 患儿与非 IBD 患儿发生 VTE 的相对风险在年龄较小的患者群体中最大:0 至 8 岁年龄段的相对风险为 96.5(95% CI,51.8-179.9),9 至 11 岁年龄段的相对风险为 153.1(95% CI,81.2-288.8),15 至 17 岁年龄段的相对风险为 14.3(95% CI,10.3-20.0)。IBD患者脑静脉窦血栓形成占小儿VTE事件的17.6%,而无IBD儿童仅为4.2%(P = .001):本研究证实,与无 IBD 儿童相比,IBD 儿童发生 VTE 的风险更高。VTE 风险最大的时间是在诊断前后。脑静脉窦血栓形成在IBD患儿中的发生率明显高于其他患儿。
{"title":"The Risk of Venous Thromboembolism in Children With Inflammatory Bowel Disease.","authors":"Philip R Harvey, David McNulty, Benjamin Coupland, Polychronis Kemos, Nicholas M Croft, Nigel J Trudgill","doi":"10.1093/ibd/izae249","DOIUrl":"https://doi.org/10.1093/ibd/izae249","url":null,"abstract":"<p><strong>Background: </strong>Recent studies of children with inflammatory bowel disease (IBD) demonstrate an increased venous thromboembolism (VTE) risk. However, estimates of risk are variable and case numbers are limited. The aim of this study was to provide national estimates of the risk of VTE in children with IBD.</p><p><strong>Methods: </strong>Hospital Episode Statistics was used to identify patients diagnosed with either IBD or VTE before reaching 18 years of age between 2001 and 2019. Populations and subgroups are described, and the risks of developing VTE in the general and IBD populations were calculated.</p><p><strong>Results: </strong>Children with VTE following a diagnosis of IBD or in the previous 6 months (n = 85) and with VTE without IBD (n = 4160) were studied. The absolute risk in children with IBD was 9.42 (95% confidence interval [CI], 7.4-11.4) per 10 000 patient-years, compared with 0.18 (95% CI, 18-0.19) in children without IBD. Between 6 months prior to and 1 year following IBD diagnosis was the highest absolute risk period for VTE (18.0; 95% CI, 13.7-22.4). The relative risk of VTE in children with IBD vs children without IBD was greatest in younger patient groups: the relative risk for the age band 0 to 8 years was 96.5 (95% CI, 51.8-179.9) and for 9 to 11 years was 153.1 (95% CI, 81.2-288.8) vs 14.3 (95% CI, 10.3-20.0) for 15 to 17 years. Cerebral venous sinus thrombosis represented 17.6% of pediatric VTE events in IBD patients compared with 4.2% in children without IBD (P = .001).</p><p><strong>Conclusions: </strong>This study confirms the increased risk of VTE in children with IBD compared with children without IBD. The time of greatest VTE risk was around diagnosis. Cerebral venous sinus thrombosis was significantly more common in children with IBD than other children.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biologics and Oral Small Molecules Are Not Associated With Increased Major Adverse Cardiovascular Events or Venous Thromboembolism in Inflammatory Bowel Disease. 生物制剂和口服小分子药物与炎症性肠病主要不良心血管事件或静脉血栓栓塞的增加无关。
IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-13 DOI: 10.1093/ibd/izae267
Thabet Qapaja, Mohammed Abu-Rumaileh, Khaled Alsabbagh Alchirazi, Ahmad Gharaibeh, Ahmad Naser, Osama Hamid, Dina Alayan, Miguel Regueiro

Background: Biologics and oral small molecules (OSM) effectively treat inflammatory bowel disease (IBD), but some are linked to higher risks of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). This study evaluates the MACE and VTE risks in IBD patients treated with biologics or OSM.

Methods: Using the TrinNetX multi-institutional database, we examined MACE and VTE in adult IBD patients on biologics and compared them to IBD patients not on biologics. We also compared IBD patients on OSM to those not on OSM. We performed 1:1 propensity score matching. MACE (myocardial infarction [MI], stroke, and all-cause mortality) and VTE were assessed from 30 days to 3 years after drug prescription.

Results: After matching, IBD patients on biologics had reduced risk of MI, stroke, and all-cause mortality at 1 year, compared to those not on biologics (P < .05). No significant difference in VTE was observed (P = .5). At 3 years, biologic-treated patients had lower risks of MI, stroke, all-cause mortality, and VTE (P < .05). Inflammatory bowel disease patients on OSM showed no significant differences in MI, stroke, or VTE at 1 and 3 years, but had lower all-cause mortality (P < .05). In older IBD patients with at least 1 cardiovascular risk factor, OSM usage showed no significant difference in MI, stroke, or VTE risk compared to nonusers; however, all-cause mortality was decreased at 3 years (P < .05).

Conclusions: Inflammatory bowel disease patients treated with biologics or OSM were not at increased risk of MACE or VTE. Although further studies and longer follow-up periods are needed to confirm these findings, our results provide reassurance regarding the safety of these medications in IBD.

背景:生物制剂和口服小分子药物(OSM)能有效治疗炎症性肠病(IBD),但其中一些药物与较高的主要不良心血管事件(MACE)和静脉血栓栓塞(VTE)风险有关。本研究评估了接受生物制剂或OSM治疗的IBD患者的MACE和VTE风险:利用 TrinNetX 多机构数据库,我们研究了接受生物制剂治疗的成年 IBD 患者的 MACE 和 VTE,并与未接受生物制剂治疗的 IBD 患者进行了比较。我们还将使用 OSM 的 IBD 患者与未使用 OSM 的患者进行了比较。我们进行了 1:1 倾向评分匹配。对用药后30天至3年的MACE(心肌梗死、中风和全因死亡率)和VTE进行了评估:结果:匹配后,与未使用生物制剂的患者相比,使用生物制剂的 IBD 患者在 1 年后发生心肌梗死、中风和全因死亡的风险降低(P接受生物制剂或OSM治疗的炎症性肠病患者发生MACE或VTE的风险并没有增加。虽然还需要进一步的研究和更长的随访期来证实这些发现,但我们的研究结果为这些药物在 IBD 患者中的安全性提供了保证。
{"title":"Biologics and Oral Small Molecules Are Not Associated With Increased Major Adverse Cardiovascular Events or Venous Thromboembolism in Inflammatory Bowel Disease.","authors":"Thabet Qapaja, Mohammed Abu-Rumaileh, Khaled Alsabbagh Alchirazi, Ahmad Gharaibeh, Ahmad Naser, Osama Hamid, Dina Alayan, Miguel Regueiro","doi":"10.1093/ibd/izae267","DOIUrl":"https://doi.org/10.1093/ibd/izae267","url":null,"abstract":"<p><strong>Background: </strong>Biologics and oral small molecules (OSM) effectively treat inflammatory bowel disease (IBD), but some are linked to higher risks of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). This study evaluates the MACE and VTE risks in IBD patients treated with biologics or OSM.</p><p><strong>Methods: </strong>Using the TrinNetX multi-institutional database, we examined MACE and VTE in adult IBD patients on biologics and compared them to IBD patients not on biologics. We also compared IBD patients on OSM to those not on OSM. We performed 1:1 propensity score matching. MACE (myocardial infarction [MI], stroke, and all-cause mortality) and VTE were assessed from 30 days to 3 years after drug prescription.</p><p><strong>Results: </strong>After matching, IBD patients on biologics had reduced risk of MI, stroke, and all-cause mortality at 1 year, compared to those not on biologics (P < .05). No significant difference in VTE was observed (P = .5). At 3 years, biologic-treated patients had lower risks of MI, stroke, all-cause mortality, and VTE (P < .05). Inflammatory bowel disease patients on OSM showed no significant differences in MI, stroke, or VTE at 1 and 3 years, but had lower all-cause mortality (P < .05). In older IBD patients with at least 1 cardiovascular risk factor, OSM usage showed no significant difference in MI, stroke, or VTE risk compared to nonusers; however, all-cause mortality was decreased at 3 years (P < .05).</p><p><strong>Conclusions: </strong>Inflammatory bowel disease patients treated with biologics or OSM were not at increased risk of MACE or VTE. Although further studies and longer follow-up periods are needed to confirm these findings, our results provide reassurance regarding the safety of these medications in IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. 更正:溃疡性结肠炎患者接受依曲莫德治疗后与健康相关的生活质量结果:对 ELEVATE UC 52 和 ELEVATE UC 12 数据的事后分析。
IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-13 DOI: 10.1093/ibd/izae252
{"title":"Correction to: Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12.","authors":"","doi":"10.1093/ibd/izae252","DOIUrl":"https://doi.org/10.1093/ibd/izae252","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Bidirectional Relationship Between Sleep and Pain in Crohn's Disease: A Daily Diary Study. 克罗恩病患者睡眠与疼痛之间的双向关系:每日日记研究
IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-12 DOI: 10.1093/ibd/izae265
Jessica K Salwen-Deremer, Sarah J Westvold, Corey A Siegel, Michael T Smith

Background: Pain is common in Crohn's disease (CD) even after endoscopic healing is achieved. Depression, sleep disturbances, fatigue, and worry about pain impact the pain experience. There is a bidirectional relationship between sleep and pain, though it has received minimal attention in CD. Herein, we sought to comprehensively assess this relationship in CD using daily diaries.

Method: Patients with active symptoms of insomnia and CD were recruited as part of an ongoing clinical trial. Participants completed 14-day diaries on sleep patterns and CD symptoms. Temporal associations between sleep and pain were assessed using cross-lagged path analysis and controlled for age, sex, and menstrual cycle.

Results: Overall, 26 participants completed 14-day diaries. All assessed aspects of sleep continuity disturbance were associated with worse next-day abdominal pain (Ps < 0.01). When assessed microlongitudinally, sleep onset latency predicted next-day pain (P = 0.07) and vice versa (P = 0.03). Similarly, nightly awakenings predicted next day pain (P = 0.02) and vice versa (P = 0.04). Sleep efficiency (P = 0.003), sleep quality (P < 0.001), and total sleep time (P = 0.04) predicted next-day pain whereas models with pain as the predictor were not significant.

Conclusions: Sleep continuity and abdominal pain are closely related, with sleep efficiency, total sleep time, and sleep quality potentially driving next-day abdominal pain. As interventions for pain in IBD are limited, it may be important to capitalize on the impact of sleep disturbances on pain to optimize overall wellbeing in people with CD.

背景:克罗恩病(CD)患者即使在内镜治疗痊愈后仍会感到疼痛。抑郁、睡眠障碍、疲劳和对疼痛的担忧都会影响疼痛体验。睡眠与疼痛之间存在双向关系,但在克罗恩病中却很少受到关注。在此,我们试图通过每日日记来全面评估 CD 中的这种关系:方法:作为一项正在进行的临床试验的一部分,我们招募了具有活动性失眠症状的 CD 患者。参与者填写了 14 天的睡眠模式和 CD 症状日记。采用交叉滞后路径分析评估了睡眠与疼痛之间的时间关联,并对年龄、性别和月经周期进行了控制:共有 26 名参与者完成了 14 天的日记。结果:共有 26 名参与者完成了 14 天的日记,所有被评估的睡眠连续性障碍都与次日腹痛的恶化有关(Ps 结论:睡眠连续性与腹痛之间存在密切联系:睡眠连续性与腹痛密切相关,睡眠效率、总睡眠时间和睡眠质量可能会影响第二天的腹痛。由于针对 IBD 疼痛的干预措施有限,因此利用睡眠障碍对疼痛的影响来优化 CD 患者的整体健康可能非常重要。
{"title":"The Bidirectional Relationship Between Sleep and Pain in Crohn's Disease: A Daily Diary Study.","authors":"Jessica K Salwen-Deremer, Sarah J Westvold, Corey A Siegel, Michael T Smith","doi":"10.1093/ibd/izae265","DOIUrl":"https://doi.org/10.1093/ibd/izae265","url":null,"abstract":"<p><strong>Background: </strong>Pain is common in Crohn's disease (CD) even after endoscopic healing is achieved. Depression, sleep disturbances, fatigue, and worry about pain impact the pain experience. There is a bidirectional relationship between sleep and pain, though it has received minimal attention in CD. Herein, we sought to comprehensively assess this relationship in CD using daily diaries.</p><p><strong>Method: </strong>Patients with active symptoms of insomnia and CD were recruited as part of an ongoing clinical trial. Participants completed 14-day diaries on sleep patterns and CD symptoms. Temporal associations between sleep and pain were assessed using cross-lagged path analysis and controlled for age, sex, and menstrual cycle.</p><p><strong>Results: </strong>Overall, 26 participants completed 14-day diaries. All assessed aspects of sleep continuity disturbance were associated with worse next-day abdominal pain (Ps < 0.01). When assessed microlongitudinally, sleep onset latency predicted next-day pain (P = 0.07) and vice versa (P = 0.03). Similarly, nightly awakenings predicted next day pain (P = 0.02) and vice versa (P = 0.04). Sleep efficiency (P = 0.003), sleep quality (P < 0.001), and total sleep time (P = 0.04) predicted next-day pain whereas models with pain as the predictor were not significant.</p><p><strong>Conclusions: </strong>Sleep continuity and abdominal pain are closely related, with sleep efficiency, total sleep time, and sleep quality potentially driving next-day abdominal pain. As interventions for pain in IBD are limited, it may be important to capitalize on the impact of sleep disturbances on pain to optimize overall wellbeing in people with CD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stricturing Crohn's Disease: When Biologics May Help or Not? 严格控制克罗恩病:生物制剂到底有没有用?
IF 4.5 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-11-12 DOI: 10.1093/ibd/izae264
Kush Fansiwala, Berkeley N Limketkai
{"title":"Stricturing Crohn's Disease: When Biologics May Help or Not?","authors":"Kush Fansiwala, Berkeley N Limketkai","doi":"10.1093/ibd/izae264","DOIUrl":"https://doi.org/10.1093/ibd/izae264","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Inflammatory Bowel Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1